87 related articles for article (PubMed ID: 19373032)
1. Protease inhibitor therapy in resource-limited settings.
Elliott JH; Pujari S
Curr Opin HIV AIDS; 2008 Nov; 3(6):612-9. PubMed ID: 19373032
[TBL] [Abstract][Full Text] [Related]
2. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
Sahali S; Chaix ML; Delfraissy JF; Ghosn J
AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
[TBL] [Abstract][Full Text] [Related]
4. Toxicity of HIV protease inhibitors: clinical considerations.
Boesecke C; Cooper DA
Curr Opin HIV AIDS; 2008 Nov; 3(6):653-9. PubMed ID: 19373038
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
6. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes.
Blaschke TF
Curr Opin HIV AIDS; 2008 Nov; 3(6):603-7. PubMed ID: 19373030
[TBL] [Abstract][Full Text] [Related]
7. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of HIV protease inhibitors in pregnancy.
van der Lugt J; Colbers A; Burger D
Curr Opin HIV AIDS; 2008 Nov; 3(6):620-6. PubMed ID: 19373033
[TBL] [Abstract][Full Text] [Related]
10. Warfarin-antiretroviral interactions.
Liedtke MD; Rathbun RC
Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
[TBL] [Abstract][Full Text] [Related]
11. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?
Winston A; Khoo S
Curr Opin HIV AIDS; 2008 Nov; 3(6):608-11. PubMed ID: 19373031
[TBL] [Abstract][Full Text] [Related]
13. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
Cozzi-Lepri A; Phillips AN; Martinez-Picado J; Monforte Ad; Katlama C; Eg Hansen AB; Horban A; Bruun J; Clotet B; Lundgren JD;
J Infect Dis; 2009 Sep; 200(5):687-97. PubMed ID: 19604043
[TBL] [Abstract][Full Text] [Related]
14. Research needs and challenges in the development of HIV diagnostic and treatment monitoring tests for use in resource-limited settings.
Cheng B; Landay A; Miller V
Curr Opin HIV AIDS; 2008 Jul; 3(4):495-503. PubMed ID: 19373011
[TBL] [Abstract][Full Text] [Related]
15. Interactions between antiretroviral agents and those used to treat tuberculosis.
Bonora S; Di Perri G
Curr Opin HIV AIDS; 2008 May; 3(3):306-12. PubMed ID: 19372983
[TBL] [Abstract][Full Text] [Related]
16. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
[TBL] [Abstract][Full Text] [Related]
17. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Müller L; Singer T
Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and management of early virological failure.
Sax PE
Curr Opin HIV AIDS; 2006 Sep; 1(5):409-16. PubMed ID: 19372840
[TBL] [Abstract][Full Text] [Related]
19. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.
Kiser JJ
Curr Opin HIV AIDS; 2008 May; 3(3):330-41. PubMed ID: 19372987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
